Drugs / BMS-986258
BMS-986258
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03446040 | Mar 2018 → Aug 2024 | cancer of unknown primary site | Bristol-Myers Squibb | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BMS-986258 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03446040 ↗ |
| Known as | Anti-tim-3 antibody bms-986258 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297708 ↗ |
| Known as | ONO-7807 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297708 ↗ |